These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36971825)

  • 1. Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
    Busetto GM; Finati M; Chirico M; Cinelli F; D'Altilia N; Falagario UG; Sanguedolce F; Del Giudice F; De Berardinis E; Ferro M; Crocetto F; Porreca A; Di Gianfrancesco L; Calo' B; Mancini V; Bettocchi C; Carrieri G; Cormio L
    World J Urol; 2023 May; 41(5):1329-1335. PubMed ID: 36971825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
    Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
    Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure.
    Sanz Gómez I; Huguet J; Bravo A; Robalino J; Rodríguez Faba Ó; Territo Á; Gaya JM; Palou J; Breda A
    Clin Genitourin Cancer; 2023 Aug; 21(4):e286-e290. PubMed ID: 37076337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer.
    Melgarejo-Segura MT; Morales-Martínez A; Yáñez-Castillo Y; Arrabal-Polo MÁ; Gómez-Lechuga P; Pareja-Vílchez M; Jiménez-Moleón JJ; Martín MA
    Urol Oncol; 2023 Apr; 41(4):166-176. PubMed ID: 36328923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
    Arrabal Polo MÁ; Melgarejo Segura MT; Yáñez Castillo Y; Morales Martínez A; Pareja Vílchez M; Arrabal Martín M
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7453-7459. PubMed ID: 36952006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
    BMC Cancer; 2018 Dec; 18(1):1224. PubMed ID: 30522445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
    Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Melgarejo Segura MT; Morales Martínez A; Yáñez Castillo Y; Arrabal Polo MÁ; Gómez Lechuga P; Pareja Vílchez M; Arrabal Martín M
    Urol Oncol; 2023 Feb; 41(2):109.e1-109.e8. PubMed ID: 36379812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.
    Balasubramanian A; Gunjur A; Weickhardt A; Papa N; Bolton D; Lawrentschuk N; Perera M
    World J Urol; 2022 May; 40(5):1111-1124. PubMed ID: 35083522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
    Di Stasi SM; Riedl C
    World J Urol; 2009 Jun; 27(3):325-30. PubMed ID: 19234707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No clinical benefit from sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) than BCG alone in the adjuvant treatment of high risk non muscle invasive bladder cancer: result of a planned interim analysis of a prospective randomized trial.
    Cicione A; Lombardo R; Nacchia A; Franco A; Simone G; Pastore A; Leonardo C; Franco G; Tubaro A; DE Nunzio C
    Minerva Urol Nephrol; 2024 Aug; 76(4):458-466. PubMed ID: 38842053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
    Hayne D; Stockler M; McCombie SP; Chalasani V; Long A; Martin A; Sengupta S; Davis ID
    BMC Cancer; 2015 May; 15():432. PubMed ID: 26014129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance.
    Akbulut F; Pazir Y; Esmeray A; Erbin A; Ozgor F; Sarilar O
    Urologia; 2023 Nov; 90(4):631-635. PubMed ID: 37470319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.